Cargando…

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents

Treg modulation has been hypothesized as one of the mechanisms by which antitumor necrosis factor α (TNFα) agents exert their action in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). However, data in IBD are still conflicting. We evaluated CD4(+)CD25(+)FOXP3(+) (Tregs) by flow cytom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guidi, Luisa, Felice, Carla, Procoli, Annabella, Bonanno, Giuseppina, Martinelli, Enrica, Marzo, Manuela, Mocci, Giammarco, Pugliese, Daniela, Andrisani, Gianluca, Danese, Silvio, De Vitis, Italo, Papa, Alfredo, Armuzzi, Alessandro, Rutella, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766994/ https://www.ncbi.nlm.nih.gov/pubmed/24063002 http://dx.doi.org/10.1155/2013/286368

Ejemplares similares

Treatment of Crohn’s disease with colony-stimulating factors: An overview
por: Guidi, Luisa, et al.
Publicado: (2008)

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2018)

Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies
por: Bonanno, Giuseppina, et al.
Publicado: (2010)

Interleukin-21 induces the differentiation of human umbilical cord blood CD34(-)lineage(- )cells into pseudomature lytic NK cells
por: Bonanno, Giuseppina, et al.
Publicado: (2009)

Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
por: Iachininoto, Maria Grazia, et al.
Publicado: (2013)

Mucosal healing in ulcerative colitis: surveillance or colectomy?
por: Andrisani, Gianluca, et al.
Publicado: (2013)

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
por: Bonanno, Giuseppina, et al.
Publicado: (2010)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
por: Bonanno, Giuseppina, et al.
Publicado: (2012)

Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011)

The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis
por: Genua, Marco, et al.
Publicado: (2014)

Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
por: Papa, Alfredo, et al.
Publicado: (2022)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis
por: Alivernini, Stefano, et al.
Publicado: (2018)

Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement
por: Graffigna, Guendalina, et al.
Publicado: (2021)

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study
por: Magrì, Salvatore, et al.
Publicado: (2022)

Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
por: Daperno, Marco, et al.
Publicado: (2019)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance
por: Ganapathi, S K, et al.
Publicado: (2014)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine
por: Felice, Carla, et al.
Publicado: (2019)

Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
por: Festa, Stefano, et al.
Publicado: (2021)

Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?
por: Armuzzi, Alessandro, et al.
Publicado: (2022)

Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy
por: Pietropaolo, Giuseppe, et al.
Publicado: (2020)

Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery
por: Papa, Alfredo, et al.
Publicado: (2020)

Natalizumab in Crohn's disease: past and future areas of applicability
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature
por: Rutella, Sergio, et al.
Publicado: (2011)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

M tuberculosis in the Adjuvant Modulates Time of Appearance of CNS-Specific Effector T Cells in the Spleen through a Polymorphic Site of TLR2
por: Nicolò, Chiara, et al.
Publicado: (2013)

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study
por: Pugliese, Daniela, et al.
Publicado: (2018)

Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach
por: Corsello, Antonio, et al.
Publicado: (2021)

Frontiers in Drug Research and Development for Inflammatory Bowel Disease
por: Currò, Diego, et al.
Publicado: (2017)

FOXP2
por: Nudel, Ron, et al.
Publicado: (2013)

Orphan patients with inflammatory bowel disease - when we treat beyond evidence
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
por: Kristensen, Lars Erik, et al.
Publicado: (2023)

Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology
por: Yadav, Santosh K., et al.
Publicado: (2015)

Liver tests abnormalities in COVID-19: trick or treat?
por: Vespa, Edoardo, et al.
Publicado: (2020)

Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3(+) and Foxp3(−) T cells
por: Franckaert, Dean, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dtpf7aod8l5ocaskn99t1tdttk